tbuckley/cabot-search huggingface dataset:
Reply
Authors: Laura Kulik, Riad Salem
Journal: Hepatology (2009)

We thank Professor Strunk for his interest in our article and appreciate the comments. It is our pleasure to reply to each query. In this 108-patient cohort, radioembolization was always performed either at the lobar or segmental hepatic artery level. Our group has always advocated against the use of whole-liver 90Y treatment, particularly in the patient with cirrhosis who has hepatocellular carcinoma. Although table 1 states that most patients had <50% tumor burden, most of these tumors were large and involved many segments. Hence, it was our standard to inject at the lobar hepatic artery level. When smaller tumors were encountered, a segmental injection was performed in order to spare liver parenchyma from unnecessary radiation. We have never injected 90Y at the proper or common hepatic artery level and do not advocate this approach. The microsphere device used in the study was glass-based. It is well-known that this device delivers a small volume of microspheres with very high specific activity. Hence, this represents an arterial microembolization rather than a macroembolization procedure. As a result, we are always able to inject the prescribed dose; embolization and flow stasis are not factors using this technique. This angiographic concept has been previously described by our group.1 Professor Strunk may be referring to resin microspheres for the treatment of hepatocellular carcinoma. The resin-based device has different radioembolic properties, and therefore flow stasis is more of a factor during the injection process.2 The differences between glass and resin devices are thoroughly summarized by Murthy et al.3 With respect to the errors in the manuscript, we apologize for the oversight. Indeed, for table 1, it should state "71" rather than "1" for the number of patients. In table 2, it should also state "<50" rather than ">50" in the section on tumor burden. Laura Kulik M.D.*, Riad Salem M.D., M.B.A.*, * Northwestern University, Chicago, IL.
FROM OTHER PAGES
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A phase I/II study of bavituximab and sorafenib in advanced hepatocellular carcinoma (HCC).
Authors: Adam Charles Yopp, Amit G. Singal, Yull Edwin Arriaga, Udit N. Verma, Joseph Shan, Nikoletta L. Kallinteris, Muhammad Shaalan Beg, John C. Mansour, Hao Zhu
Journal: Journal of Clinical Oncology (2015)

4109 Background: Bavituximab, a first-in-class immunomodulator targeting phosphatidylserine (PS), a membrane lipid externalized on tumor and endothelial cells. In preclinical HCC models, sorafenib upregulated PS externalization providing more bavituximab targets altering the tumor environment from immunosuppressive to immunoreactive. Methods: In the 3+3 phase I trial, adults with advanced HCC, ECOG PS ≤ 2, and Child-Pugh class A or B7 received escalating doses of bavituximab weekly (0.3, 1, and 3 mg/kg) and sorafenib 400 mg bid for one 4-week cycle to determine the MTD of bavituximab. In the phase II trial with the same eligibility, patients received 3 mg/kg bavituximab and sorafenib until progression or toxicity. The primary endpoint was radiologic time to progression (TTP). Secondary endpoints included safety, 4-month progression free survival (PFS), overall survival (OS), and response rates. Correlative studies from pre- and post-treatment tumor biopsies included IHC analysis of immune infiltrates. Results: Ten patients were enrolled in the phase I trial without DLTs, demonstrating a MTD of 3 mg/kg of bavituximab and 400 mg PO of sorafenib. In the phase II trial, 38 patients were accrued, with 4 remaining on treatment at the time of this submission. Median follow-up is 6.1 months. Patient characteristics: median age: 60.5 years, male: 74%, HCV: 79%, macrovascular invasion: 84%, previous treatment: 40%, and metastases: 24%. Median TTP is 6.7 months (95%CI 4,14). Median OS is 6.2 months (95%CI 5,7). Four month PFS is 61% and two patients achieved partial response. Treatment related AEs include seven grade 3 but no grade 4 or 5 events. Most common all grade events were diarrhea (32%), fatigue (26%), and anorexia (24%). Six patients had tissue analyzed pre- and post-treatment, two of the six had significant increase tumor infiltration of CD4+, CD8+, and macrophages with a corresponding decrease in T regulatory cells. Conclusions: Bavituximab and sorafenib were well tolerated in advanced HCC. When compared with historical controls, combination therapy in a patient population with more unfavorable disease biology demonstrated an improvement in TTP and 4-month PFS. Combination therapy increased immune tumor infiltrates. Clinical trial information: NCT01264705.
Injection of collagenase in the treatment of herniated lumbar disk. Initial clinical report
Authors: B. J. Sussman
Journal: JAMA (1981)

Twenty-nine patients with persistent, low back and sciatic pain received intradiscal collagenase at a single abnormal disk space after two months of conservative therapy and two weeks of additional bed rest. Complete pain relief was achieved in six patients (21%), notable relief in 12 (42%), moderate in six (21%), and slight in one. Four patients (14%) who obtained no improvement by enzyme injection recovered after extruded disk fragments were removed from the spinal canal during a later operation. Pain relief after collagenase injection took place gradually over a two- to three-week period and was associated with some early backache. Improvement then continued at a slower rate for two to three months. There were no adverse effects of enzyme therapy. Injected disk spaces usually showed radiological narrowing. (<i>JAMA</i>1981;245:730-732)
Abstract 3590: Mechanisms and inhibition RIOK2 for obesity-driven prostate cancer
Authors: Everardo Macias, Jiyoon Cho, Drew Rosowicz, Zahra Heidari, Sungyong You, Erick J. Maravilla, Jen-Tsan Chi, Stephen J. Freedland
Journal: Cancer Research (2019)

Abstract Obesity is associated with greater risk of high-grade prostate cancer (PC), recurrence after therapy, metastases, and PC specific mortality. The fact that obesity is a PC risk factor creates an opportunity to identify and target the mechanisms underlying obesity-enhanced lethal PC. We exploited this link by performing an shRNA in vivo screen in obese mice targeting the entire kinome, which found Right Open Reading Frame Kinase 2 (RIOK2) as essential for PCs in obese mice. We found RIOK2 gene signature is correlated with a 56% increased risk of metastatic PC. Moreover, when we queried only men with a BMI ≥ 30 kg/m2 we found that high levels of RIOK2 gene signature increased the risk of metastasis by an additional 50%. RIOK2, a serine/threonine kinase, is critical for de novo ribosome maturation and assembly, which is essential to maintain the high proliferation rates in cancer cells. Indeed, we found that RIOK2 loss reduced de novo protein synthesis in PC cells and decreased cell viability. Conversely, RIOK2 overexpression enhanced PC cell growth. As our goal is to find actionable PC targets to reduce obesity effects on PC, we conducted a protein structure based compound screen in silico and identified a lead kinase inhibitor of RIOK2 (kiRIOK2). Our lead kiRIOK2 inhibits cell proliferation, protein synthesis, anchorage-independent growth and invasion of multiple PC lines in the µM range. SAR optimized kiRIOK2 have increased efficacy and bioavailability. Our studies are providing probes and mechanistic insights to further investigate the role of RIOK2 in PC biology. In the long-term, this may help mitigate the added risk of obesity on PC metastasis and PC-specific mortality. Citation Format: Everardo Macias, Jiyoon Cho, Drew Rosowicz, Zahra Heidari, Sungyong You, Erick J. Maravilla, Jen-Tsan Chi, Stephen J. Freedland. Mechanisms and inhibition RIOK2 for obesity-driven prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3590.
Twenty times-less liver laminin as compared to laminins 1 and 2 is required for hepatocyte attachment in vitro , Liver Research Center and Departments of Medicine and Pathology, Albert Einstein College of Medicine, Bronx, N.Y.
Journal: Hepatology (1995)

The expression and cellular distribution of desmin, alpha-smooth muscle actin (A-SMA) and cytokeratin no. 8 (CK-8) and no. 18 (CK-18) in normal adult, neonatal and fetal rat liver were examined immunohistochemically on cryostat sections. At days 14 and 15 of gestation, nonhematopoietic cells in embryonic liver were strongly desmin-positive, and some of the cells, mainly located in the periphery, were also stained with anti-A-SMA. Desmin immunoreactivity gradually decreased from day 16 of gestation. A close association of desmin-positive cell processes with hematopoietic cells was observed during fetal and early neonatal development. From day 16 of gestation the prehepatocytes became desmin-negative, remained CK-8 and CK-18 positive. Desmin-expressing cells were numerous in the liver from the embryonic period to the neonatal age. However, their absolute number per unit area, as well as their number relative to hepatocytes, decreased with age. We suggest that desmin-positive cells in embryonic liver may act as stromal cells in the hepatic hematopoietic microenvironment and support hepatocyte development.
Abstract 2230: Lower Extremity Counterpulsation During The Decompression Phase of CPR Improves Hemodynamics And Provides Continuous Forward Carotid Blood Flow.
Authors: Demetris Yannopoulos, Henry R Halperin, Johns Hopkins, Keith G Lurie
Journal: Circulation (2007)

Background: We hypothesize that lower extremity counterpulsations (LECP) during the decompression phase of CPR will increase diastolic aortic pressure without raising the intracranial pressure (ICP) and significantly increase forward carotid blood flow. Methods: In 6 (24±4Kg) pigs, 4 minutes of untreated VF were followed by 2 minutes epochs of standard (STD) CPR, STD +LECP, active compression decompression (ACD) +ITD and ACD + inspiratory impedance threshold device (ITD)+LECP. Compressions and ventilations were performed according to the 2005 AHA guidelines. A large blood pressure cuff that was circumferentially placed around the pig’s thighs avoiding the abdominal cavity was inflated with air to the point that manometer pressure started to rise. Compressions over the cuff were performed manually and synchronized with the thoracic decompression phase. The cuff was compressed up to 200mmHg. Basic hemodynamic parameters and common carotid blood flow (CCBF) (ml/min) were continuously measured. Cerebral perfusion pressure (CerPP) (mean arterial pressure - mean ICP) and CPP (diastolic AoP - diastolic RAP) were calculated at the end of the 2 minute epochs. Statistical analysis was performed with ANOVA. Results: LECP significantly increased diastolic aortic pressure, CPP and CerPP both when added on STD and on ACD+ITD CPR. The largest benefit was observed with ACD+ITD+LECP were there was a 2-fold increase in CPP and CerPP with a 2.5-fold increase in common carotid blood flow compared to STD CPR. LECP did not alter ICP. (Table 1 ). Decompression phase CCBF during ACD+ITD+LECP CPR was positive and reached pre cardiac arrest levels. Conclusion: LECP during thoracic decompression significantly augmented aortic diastolic pressure, CPP and CerPP without increasing the ICP . LECP led to a continuous positive cerebral perfusion pressure gradient during CPR cycles and in combination with ACD + ITD CPR common carotid blood flow reached pre-arrest levels. Hemodynamic Parameters
Ototoxicity in children receiving platinum chemotherapy: Underestimating a commonly occurring toxicity that may impact academic and social development
Authors: E. A. Neuwelt, K. Gilmer Knight, D. Kraemer
Journal: Journal of Clinical Oncology (2005)

8548 Purpose: To describe the frequency and severity of ototoxicity in a series of pediatric patients treated with platinum-based chemotherapy. Methods: Serial audiologic evaluations were conducted for 67 subjects aged 8 months to 23 years who received platinum-based chemotherapy. Audiologic data was analyzed to determine time to hearing-loss using American Speech-Language-Hearing Association (ASHA) criteria, and the effects of treatment and patient characteristics on the incidence and severity of ototoxicity. Results: Bilateral decreases in hearing were seen in 61% of patients (median time-to-hearing-loss 135 days). Children treated for medulloblastoma, osteosarcoma and neuroblastoma had greater incidence and severity of hearing loss. Agreement between the usually reported National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) and ASHA criteria was inadequate. Conclusions: Traditional reporting of toxicity data (CTCAE) has under-reported ototoxicity and minimized the significance of hearing loss in children. As pediatric patients experience improved survival, the affects and implications of high frequency hearing loss in regards to academic achievement and speech and language development are important considerations, especially in patients younger than 5 years. No significant financial relationships to disclose.
Hypertension management program in an industrial community
Authors: R. C. Charman
Journal: JAMA (1974)

Detection and adequate management of patients with high blood pressure remain major problems in preventive medicine in the United States. We utilized community physicians, medical center planning, and organization of existing community resources to develop a model blood pressure control program in a rural area 200 miles from the Dartmouth-Hitchcock Medical Center. One thousand seven hundred forty subjects were screened for the presence of elevated blood pressure. One hundred four subjects were found to have elevated blood pressure after three determinations and were classified into groups for further treatment. Follow-up on 102 of these subjects showed that 88% saw their physician within two months and 86% were being followed-up regularly after one year by their community physicians. Eighty-six percent of the subjects with diastolic blood pressures greater than 100 mm Hg were still receiving drug therapy after one year follow-up.
Treatment of Hospitalized Schizophrenics with Trifluoperazine plus Tranylcypromine: A Double-Blind Controlled Study
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prevention and treatment of gas gangrene
Authors: W. A. Altemeier
Journal: JAMA (1971)

Analysis of a series of 54 cases of gas gangrene with a yearly incidence of 1.8 cases emphasizes the infrequency of its occurrence.<i>Clostridium perfringens</i>was cultured in 95% of the cases,<i>C novyi</i>in 8%, and C septicum in 4%. The mortality was 14.8%. Clinical classifications of clostridial infection and nonclostridial crepitant lesions emphasize differential diagnostic points. Prevention of gas gangrene is accomplished by early, adequate debridement of wounds. Prophylactic serotherapy or antibiotic therapy is ineffective. Primary treatment of established gas gangrene is surgical decompression or amputation of the involved part. Adjunctive intravenously administered penicillin G potassium and tetracycline hydrochloride, polyvalent gas gangrene antitoxin, and supportive therapy are used.
Chronic progressive radiation myelopathy. Its clinical aspects and differential diagnosis
Authors: T. J. Reagan
Journal: JAMA (1968)

Ten patients with chronic progressive radiation myelopathy were studied at the Mayo Clinic. Most of them had primary carcinomas of head or neck and all had received radiation therapy. The interval between termination of radiation and onset of neurologic symptoms varied from 5 1/2 to 30 months. The lower extremities were usually affected first. Sensory symptoms predominated. The spinal cord disease was cervical in eight and dorsal in two, corresponding to the segment of the cord irradiated. In four patients, the striking neurologic finding was a Brown-Séquard syndrome, whereas in six the picture was that of an incomplete transverse myelopathy. Myelograms were normal in all but one patient. Seven patients had died; average survival time was ten months. The differential diagnosis mainly concerned intramedullary tumor metastasis and "remote" carcinomatous myelopathy.
MYOCARDIAL INFARCTION
Authors: Alene Bledsoe
Journal: JAMA (1953)

<h3>To the Editor:—</h3> For some years, it has been the teaching of eminent clinicians that the beginning of myocardial infarction coincides with the onset of acute symptoms. The literature refers to "silent infarcts" (<i>Am. Pract.</i><b>4</b>:64 [Oct.] 1949), but there is little consideration of cases in which there was eventual development of the characteristic clinical picture. During a recent pathological study of coronary disease with Dr. J. B. Miale, I observed an interventricular septal rupture one day after onset of the acute coronary occlusion syndrome, recalling a similar case reported by Geckeler (<i>J. A. M. A.</i><b>148</b>:1413 [April 19] 1952). Both Geckeler and Oblath, Levinson, and Griffith (<i>J. A. M. A.</i><b>149</b>:1276 [Aug. 2] 1952) admit that well-developed myocardial necrosis is prerequisite to such rupture. According to Mallory, however, infarction necrosis of heart muscle is not well-established until the fourth day. From our own series of 84
SEROTHERAPY IN PNEUMONIA.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pseudomonas
Authors: Joan Stephenson
Journal: JAMA (2007)

A vaccine targeting proteins of the flagella of Pseudomonas aeruginosa reduced the risk of initial infection in patients with cystic fibrosis, according to German researchers (Döring G et al. Proc Natl Acad Sci U S A. doi:10.1073/pnas.0702403104 [published online ahead of print June 21, 2007]).
QUERIES AND MINOR NOTES
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Ethnic Variation, Maternal Risk Characteristics ' Among Blacks—Massachusetts, 1987 and 1988
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal